1,4-dimethylcyclohexan-1-amine | 102438-67-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1,4-dimethylcyclohexan-1-amine
• 英文别名: 1,4-dimethyl-cyclohexylamine
• CAS: 102438-67-5
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: OZPKMRTYWAJVAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,4-dimethylcyclohexan-1-amine 在 potassium permanganate 作用下， 生成 1,4-二甲基-1-硝基环己烷
  参考文献：
  名称：

  The Synthesis of Tertiary Nitroparaffins^1,2

  摘要：

  DOI：

  10.1021/ja01597a036

文献信息

• [EN] ΡΡΑRγ MODULATORS AND METHODS OF USE<br/>[FR] MODULATEURS DE ΡΡΑRγ ET MÉTHODES D'UTILISATION
  申请人：EISAI R&D MANGEMENT CO LTD

  公开号：WO2022099144A1

  公开（公告）日：2022-05-12

  Disclosed herein are novel PPARy modulators of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the same, and methods of using the same, in particular for the treatment of cancers.

  本文公开了一种新型的PPARy调节剂，其化学式为（I），以及其药学上可接受的盐，包含它们的制药组合物，以及使用它们的方法，特别是用于治疗癌症的方法。
• A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF
  申请人：Hinova Pharmaceuticals Inc.

  公开号：EP3957633A1

  公开（公告）日：2022-02-23

  The present invention relates to a class of bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof, and specifically provides a compound of formula (I), or an isotopic compound thereof, or an optical isomer thereof, or a tautomer thereof, or a pharmacologically acceptable salt thereof, or a prodrug thereof, or a solvate thereof, wherein ARB is an androgen receptor recognition/binding part, L is a link part, and U is a ubiquitin protease recognition/binding part; and the three parts are connected by means of chemical bonds. The compound can perform the targeted degradation on androgen receptors in prostate cancer cells, and suppress the proliferation of the prostate cancer cells, and also show good metabolic stability and pharmacokinetic properties. The compound has good application prospect in the preparation of targeted chimeras for protein degradation of androgen receptors and in the preparation of drugs for treating the related diseases regulated by the androgen receptors.

  本发明涉及一类用于靶向降解雄激素受体的双官能嵌合杂环化合物及其用途，具体提供了式(I)化合物，或其同位素化合物，或其光学异构体，或其同系物，或其药理学上可接受的盐，或其原药，或其溶媒，其中ARB为雄激素受体识别/结合部分，L为连接部分，U为泛素蛋白酶识别/结合部分；这三个部分通过化学键连接。该化合物能对前列腺癌细胞中的雄激素受体进行靶向降解，抑制前列腺癌细胞的增殖，并具有良好的代谢稳定性和药代动力学特性。该化合物在制备靶向降解雄激素受体蛋白的嵌合体和制备治疗受雄激素受体调控的相关疾病的药物方面具有良好的应用前景。
• FENSTER
  申请人：Merck Patent GmbH

  公开号：EP3083885B1

  公开（公告）日：2019-10-09
• VERBINDUNG
  申请人：Merck Patent GmbH

  公开号：EP3623451B1

  公开（公告）日：2021-01-20
• Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus
  申请人：Tamada Sakuya

  公开号：US20060088786A1

  公开（公告）日：2006-04-27

  A rewritable optical information recording medium including a recording layer composed of an organic dye film is provided, in which recording and erasing information can be performed reversibly by laser light irradiation. A rewritable optical information recording medium including at least one organic dye film which is substantially made of only at least one kind of organic dye compounds as a recording film is provided. The recording and erasure of information are performed by a reversible physical change of the organic dye film substance caused by laser light irradiation. Specifically, data recording is performed by a physical change locally caused by the irradiation of recording laser light, data reproduction is performed by detecting change in intensity of returned light of reproducing laser light having less power than the recording laser light, and data erasure is performed by applying at least once continuous light or pulse light having laser power more than the reproducing laser light and less than the recording laser light. The physical change is a change in shape.